Nirsevimab prophylaxis on pediatric intensive care hospitalization for severe acute bronchiolitis: a clinical and economic analysis

Abstract Background Severe acute viral bronchiolitis is a common cause of admissions to pediatric intensive care units (PICUs), resulting in a significant organizational burden each winter. The recent introduction of generalized neonatal prophylactic therapies using Nirsevimab, a monoclonal antibody...

Full description

Bibliographic Details
Published in:Annals of Intensive Care
Main Authors: Sarah Touati, Alexandre Debs, Luc Morin, Laure Jule, Caroline Claude, Pierre Tissieres, the PANDORA study group
Format: Article
Language:English
Published: SpringerOpen 2025-04-01
Subjects:
Respiratory syncytial virus
Bronchiolitis
Intensive care
Nirsevimab
Cost-effectiveness
Online Access:https://doi.org/10.1186/s13613-025-01460-0

Internet

https://doi.org/10.1186/s13613-025-01460-0

Similar Items